Anito-cel Phase One Results Published
A peer-reviewed Phase 1 study of anitocabtagene autoleucel reported responses in all 38 treated patients with heavily pretreated relapsed or refractory multiple myeloma, including 79% complete responses. At 38.1 months median follow-up, median progression-free…
